Yesu Addepalli
Research Subjects
Research Interests
Yesu Addepalli has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Zhen Wang
Chongqing University
5 shared publications - Yun He
Chongqing Key Laboratory of Natural Product Synthesis and Drug Research, School of Pharmaceutical Sciences, Chongqing University, Chongqing 401331, P. R. China
3 shared publications - Andrew Lemoff
Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, USA
2 shared publications Ann M Flusche
Department of Cell Biology, UT Southwestern Medical Center
2 shared publicationsBingnan Wang
Department of Biochemistry, UT Southwestern Medical Center
2 shared publicationsChiho Kim
Department of Biochemistry, UT Southwestern Medical Center
2 shared publications
Latest Publications
- Open Access
- 4 November 2026
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 14
Targeting tankyrase scaffolding in the β-catenin destruction complex by PROTAC overcomes the limitation of catalytic inhibitors in colorectal cancer
Aberrant WNT/β-catenin signaling drives tumorigenesis and metastasis in cancer. Although enzymatic inhibitors of tankyrase (TNKS) effectively block AXIN degradation and stabilize the β-catenin destruction complex (DC), they have demonstrated limited efficacy in various colorectal cancer (CRC) models. Here, we demonstrate that, unexpectedly, the induction of AXIN puncta represents a major barrier to achieving therapeutic efficacy. Mechanistically, catalytic inhibition of TNKS prevents TNKS turnover and drives its accumulation in the DC, wherein the scaffolding function of TNKS induces AXIN puncta formation, rigidifies the DC, and impedes β-catenin turnover. Chemically induced degradation of TNKS overcomes this limitation by stabilizing AXIN without puncta formation, providing a deeper suppression of the WNT/β-catenin pathway activity and the proliferation of CRC cells harboring dysfunctional APC mutations. Collectively, these findings provide an explanation for the unsatisfactory outcomes of drugging the WNT/β-catenin signaling pathway by TNKS inhibitors and highlight TNKS degradation as a promising approach to treat WNT/β-catenin-driven CRC.
- 4 November 2026
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 14
Open AccessTargeting tankyrase scaffolding in the β-catenin destruction complex by PROTAC overcomes the limitation of catalytic inhibitors in colorectal cancer
Aberrant WNT/β-catenin signaling drives tumorigenesis and metastasis in cancer. Although enzymatic inhibitors of tankyrase (TNKS) effectively block AXIN degradation and stabilize the β-catenin destruction complex (DC), they have demonstrated limited efficacy in various colorectal cancer (CRC) models. Here, we demonstrate that, unexpectedly, the induction of AXIN puncta represents a major barrier to achieving therapeutic efficacy. Mechanistically, catalytic inhibition of TNKS prevents TNKS turnover and drives its accumulation in the DC, wherein the scaffolding function of TNKS induces AXIN puncta formation, rigidifies the DC, and impedes β-catenin turnover. Chemically induced degradation of TNKS overcomes this limitation by stabilizing AXIN without puncta formation, providing a deeper suppression of the WNT/β-catenin pathway activity and the proliferation of CRC cells harboring dysfunctional APC mutations. Collectively, these findings provide an explanation for the unsatisfactory outcomes of drugging the WNT/β-catenin signaling pathway by TNKS inhibitors and highlight TNKS degradation as a promising approach to treat WNT/β-catenin-driven CRC.
- Open Access
- 3 August 2026
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 14
Targeting tankyrase scaffolding in the β-catenin destruction complex by PROTAC overcomes the limitation of catalytic inhibitors in cancer
Aberrant WNT/β-catenin signaling drives tumorigenesis and metastasis in cancer. Although enzymatic inhibitors of tankyrase (TNKS) effectively block AXIN degradation and stabilize the β-catenin destruction complex (DC), they have demonstrated limited efficacy in various cancer models. Here we demonstrate that, unexpectedly, the induction of AXIN puncta represents a major barrier to achieving therapeutic efficacy. Mechanistically, catalytic inhibition of TNKS prevents TNKS turnover and drives its accumulation in the DC, wherein the scaffolding function of TNKS induces AXIN puncta formation, rigidifies the DC, and impedes β-catenin turnover. Chemically induced degradation of TNKS overcomes this limitation by stabilizing AXIN without puncta formation, providing a deeper suppression of the WNT/β-catenin pathway activity and the proliferation of colorectal cancer cells harboring dysfunctional APC mutations. Collectively, these findings provide an explanation for the unsatisfactory outcomes of drugging the WNT/β-catenin signaling pathway by TNKS inhibitors and highlight TNKS degradation as a promising approach to treat WNT/β-catenin-driven cancers.
- 3 August 2026
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 14
Open AccessTargeting tankyrase scaffolding in the β-catenin destruction complex by PROTAC overcomes the limitation of catalytic inhibitors in cancer
Aberrant WNT/β-catenin signaling drives tumorigenesis and metastasis in cancer. Although enzymatic inhibitors of tankyrase (TNKS) effectively block AXIN degradation and stabilize the β-catenin destruction complex (DC), they have demonstrated limited efficacy in various cancer models. Here we demonstrate that, unexpectedly, the induction of AXIN puncta represents a major barrier to achieving therapeutic efficacy. Mechanistically, catalytic inhibition of TNKS prevents TNKS turnover and drives its accumulation in the DC, wherein the scaffolding function of TNKS induces AXIN puncta formation, rigidifies the DC, and impedes β-catenin turnover. Chemically induced degradation of TNKS overcomes this limitation by stabilizing AXIN without puncta formation, providing a deeper suppression of the WNT/β-catenin pathway activity and the proliferation of colorectal cancer cells harboring dysfunctional APC mutations. Collectively, these findings provide an explanation for the unsatisfactory outcomes of drugging the WNT/β-catenin signaling pathway by TNKS inhibitors and highlight TNKS degradation as a promising approach to treat WNT/β-catenin-driven cancers.
- Open Access
- 20 July 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-20
Benzoxazole-derivatives enhance progranulin expression and reverse the aberrant lysosomal proteome caused by GRN haploinsufficiency
Heterozygous loss-of-function mutations in the GRN gene are a major cause of hereditary frontotemporal dementia. The mechanisms linking frontotemporal dementia pathogenesis to progranulin deficiency are not well understood, and there is currently no treatment. Our strategy to prevent the onset and progression of frontotemporal dementia in patients with GRN mutations is to utilize small molecule positive regulators of GRN expression to boost progranulin levels from the remaining functional GRN allele, thus restoring progranulin levels back to normal within the brain. This work describes a series of blood-brain-barrier-penetrant small molecules which significantly increase progranulin protein levels in human cellular models, correct progranulin protein deficiency in Grn+/− mouse brains, and reverse lysosomal proteome aberrations, a phenotypic hallmark of frontotemporal dementia, more efficiently than the previously described small molecule suberoylanilide hydroxamic acid. These molecules will allow further elucidation of the cellular functions of progranulin and its role in frontotemporal dementia and will also serve as lead structures for further drug development.
- 20 July 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-20
Open AccessBenzoxazole-derivatives enhance progranulin expression and reverse the aberrant lysosomal proteome caused by GRN haploinsufficiency
Heterozygous loss-of-function mutations in the GRN gene are a major cause of hereditary frontotemporal dementia. The mechanisms linking frontotemporal dementia pathogenesis to progranulin deficiency are not well understood, and there is currently no treatment. Our strategy to prevent the onset and progression of frontotemporal dementia in patients with GRN mutations is to utilize small molecule positive regulators of GRN expression to boost progranulin levels from the remaining functional GRN allele, thus restoring progranulin levels back to normal within the brain. This work describes a series of blood-brain-barrier-penetrant small molecules which significantly increase progranulin protein levels in human cellular models, correct progranulin protein deficiency in Grn+/− mouse brains, and reverse lysosomal proteome aberrations, a phenotypic hallmark of frontotemporal dementia, more efficiently than the previously described small molecule suberoylanilide hydroxamic acid. These molecules will allow further elucidation of the cellular functions of progranulin and its role in frontotemporal dementia and will also serve as lead structures for further drug development.
- Open Access
- 12 April 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (4) , 494
Orally Bioavailable Proteolysis-Targeting Chimeras: An Innovative Approach in the Golden Era of Discovering Small-Molecule Cancer Drugs
Proteolysis-targeting chimeras (PROTACs) are an emerging therapeutic modality that show promise to open a target space not accessible to conventional small molecules via a degradation-based mechanism. PROTAC degraders, due to their bifunctional nature, which is categorized as ‘beyond the Rule of Five’, have gained attention as a distinctive therapeutic approach for oral administration in clinical settings. However, the development of PROTACs with adequate oral bioavailability remains a significant hurdle, largely due to their large size and less than ideal physical and chemical properties. This review encapsulates the latest advancements in orally delivered PROTACs that have entered clinical evaluation as well as developments highlighted in recent scholarly articles. The insights and methodologies elaborated upon in this review could be instrumental in supporting the discovery and refinement of novel PROTAC degraders aimed at the treatment of various human cancers.
- 12 April 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (4) , 494
Open AccessOrally Bioavailable Proteolysis-Targeting Chimeras: An Innovative Approach in the Golden Era of Discovering Small-Molecule Cancer Drugs
Proteolysis-targeting chimeras (PROTACs) are an emerging therapeutic modality that show promise to open a target space not accessible to conventional small molecules via a degradation-based mechanism. PROTAC degraders, due to their bifunctional nature, which is categorized as ‘beyond the Rule of Five’, have gained attention as a distinctive therapeutic approach for oral administration in clinical settings. However, the development of PROTACs with adequate oral bioavailability remains a significant hurdle, largely due to their large size and less than ideal physical and chemical properties. This review encapsulates the latest advancements in orally delivered PROTACs that have entered clinical evaluation as well as developments highlighted in recent scholarly articles. The insights and methodologies elaborated upon in this review could be instrumental in supporting the discovery and refinement of novel PROTAC degraders aimed at the treatment of various human cancers.
- Open Access
- 11 December 2023
- Published by Wiley in Chemistry – A European Journal
- Vol. 30 (7) , e202302996
Enzymatic Resolution and Decarboxylative Functionalization of α‐Sulfinyl Esters
α‐Sulfinyl esters can be readily prepared through thiol substitution of α‐bromo esters followed by oxidation to the sulfoxide. Enzymatic resolution with lipoprotein lipase provides both the unreacted esters and corresponding α‐sulfinyl carboxylic acids in high yields and enantiomeric ratios. Subsequent decarboxylative halogenation, dihalogenation, trihalogenation and cross‐coupling gives rise to functionalized sulfoxides. The method has been applied to the asymmetric synthesis of a potent inhibitor of 15‐prostaglandin dehydrogenase.
- 11 December 2023
- Published by Wiley in Chemistry – A European Journal
- Vol. 30 (7) , e202302996
Open AccessEnzymatic Resolution and Decarboxylative Functionalization of α‐Sulfinyl Esters
α‐Sulfinyl esters can be readily prepared through thiol substitution of α‐bromo esters followed by oxidation to the sulfoxide. Enzymatic resolution with lipoprotein lipase provides both the unreacted esters and corresponding α‐sulfinyl carboxylic acids in high yields and enantiomeric ratios. Subsequent decarboxylative halogenation, dihalogenation, trihalogenation and cross‐coupling gives rise to functionalized sulfoxides. The method has been applied to the asymmetric synthesis of a potent inhibitor of 15‐prostaglandin dehydrogenase.
- 11 August 2021
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 86 (17) , 12403-12411
Palladium-Catalyzed Selective [2 + 2 + 2] Annulation of 2-(2-Enynyl)pyridines with Arynes
The palladium-catalyzed chemo- and stereoselective [2 + 2 + 2] annulation reaction of 2-(2-enynyl)pyridines with arynes has been developed. A wide range of (E)- or (E/Z)-isomers of 2-(2-enynyl)pyridines and arynes was tolerated, providing a spectrum of (E)-phenanthrenylated 2-alkenylpyridines in good yield, together with the generation of a chiral axis between an alkene and a phenanthrene ring.
- 11 August 2021
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 86 (17) , 12403-12411
Palladium-Catalyzed Selective [2 + 2 + 2] Annulation of 2-(2-Enynyl)pyridines with Arynes
The palladium-catalyzed chemo- and stereoselective [2 + 2 + 2] annulation reaction of 2-(2-enynyl)pyridines with arynes has been developed. A wide range of (E)- or (E/Z)-isomers of 2-(2-enynyl)pyridines and arynes was tolerated, providing a spectrum of (E)-phenanthrenylated 2-alkenylpyridines in good yield, together with the generation of a chiral axis between an alkene and a phenanthrene ring.
- 11 September 2019
- Published by Wiley in Chemistry – An Asian Journal
- Vol. 14 (19) , 3409-3413
Phosphine‐Catalyzed [4+2] Cycloadditions of Allenic Ketones: Enantioselective Synthesis of Functionalized Tetrahydropyridines
Amino‐acid‐derived phosphine catalyzed [4+2] cycloaddition leading to chiral tetrahydropyridines, making use of α‐substituted allenic ketones as “C4 synthons” and N‐sulfonyl cyclic ketimines, has been developed. This asymmetric cycloaddition tolerates a wide range of α‐substituted allenic ketones. A series of chiral sultam‐fused tetrahydropyridines bearing a quaternary stereocenter were obtained in high yields with good enantioselectivities.
- 11 September 2019
- Published by Wiley in Chemistry – An Asian Journal
- Vol. 14 (19) , 3409-3413
Phosphine‐Catalyzed [4+2] Cycloadditions of Allenic Ketones: Enantioselective Synthesis of Functionalized Tetrahydropyridines
Amino‐acid‐derived phosphine catalyzed [4+2] cycloaddition leading to chiral tetrahydropyridines, making use of α‐substituted allenic ketones as “C4 synthons” and N‐sulfonyl cyclic ketimines, has been developed. This asymmetric cycloaddition tolerates a wide range of α‐substituted allenic ketones. A series of chiral sultam‐fused tetrahydropyridines bearing a quaternary stereocenter were obtained in high yields with good enantioselectivities.
- 3 August 2018
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 16 (33) , 6077-6085
Tandem Diels–Alder/oxidation–aromatization reactions involving 2-styrylchromones and arynes
Transition-metal-free Diels–Alder and tandem Diels–Alder/oxidation–aromatization reactions of 2-styrylchromones with arynes have been demonstrated under mild reaction conditions with a wide range of substrates. The tandem process afforded functionalized benzo[c]xanthone derivatives in moderate to good yields. This efficient protocol allows rapid access to either dihydrobenzo[c]xanthone and benzo[c]xanthone derivatives selectively by simply changing the atmosphere of the reaction.
- 3 August 2018
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 16 (33) , 6077-6085
Tandem Diels–Alder/oxidation–aromatization reactions involving 2-styrylchromones and arynes
Transition-metal-free Diels–Alder and tandem Diels–Alder/oxidation–aromatization reactions of 2-styrylchromones with arynes have been demonstrated under mild reaction conditions with a wide range of substrates. The tandem process afforded functionalized benzo[c]xanthone derivatives in moderate to good yields. This efficient protocol allows rapid access to either dihydrobenzo[c]xanthone and benzo[c]xanthone derivatives selectively by simply changing the atmosphere of the reaction.
- 23 March 2018
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 16 (16) , 2923-2931
An asymmetric Mannich reaction of α-diazocarbonyl compounds and N -sulfonyl cyclic ketimines catalyzed by complexes generated from chiral and achiral phosphines with gold( i )
An unprecedented Lewis acidic gold( i )-complex generated from chiral BINAP and PPh 3 AuCl has been developed for the Mannich reaction of α-diazocarbonyl compounds and N -sulfonyl cyclic ketimines.
- 23 March 2018
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 16 (16) , 2923-2931
An asymmetric Mannich reaction of α-diazocarbonyl compounds and N -sulfonyl cyclic ketimines catalyzed by complexes generated from chiral and achiral phosphines with gold( i )
An unprecedented Lewis acidic gold( i )-complex generated from chiral BINAP and PPh 3 AuCl has been developed for the Mannich reaction of α-diazocarbonyl compounds and N -sulfonyl cyclic ketimines.
- 16 January 2018
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 20 (3) , 644-647
Construction of Polycyclic Indole Derivatives via Multiple Aryne Reactions with Azaheptafulvenes
An efficient [8 + 2]/aryl–ene tandem reaction between azaheptafulvenes and arynes has been developed, leading to the formation of cyclohepta[b]indoles in a single step with good yield. In addition, employment of excess arynes provides a [8 + 2]/aryl–ene /[6 + 2] tandem reaction to synthesize polycyclic oxacyclohepta[b]indoles. This is the first time that azaheptafulvenes have been employed in tandem reactions with arynes.
- 16 January 2018
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 20 (3) , 644-647
Construction of Polycyclic Indole Derivatives via Multiple Aryne Reactions with Azaheptafulvenes
An efficient [8 + 2]/aryl–ene tandem reaction between azaheptafulvenes and arynes has been developed, leading to the formation of cyclohepta[b]indoles in a single step with good yield. In addition, employment of excess arynes provides a [8 + 2]/aryl–ene /[6 + 2] tandem reaction to synthesize polycyclic oxacyclohepta[b]indoles. This is the first time that azaheptafulvenes have been employed in tandem reactions with arynes.